| Name | Title | Contact Details |
|---|---|---|
Eugene Reilly |
Vice President and Chief Medical Information Officer | Profile |
Teresa Grogan |
VP and Chief Information Security Officer | Profile |
Thomas Bartiromo |
Vice President and Chief Technology Officer | Profile |
Thomas Bartiromo |
Vice President and Chief Information Officer | Profile |
Jonathan Banks |
Interim VP and Chief Information Security Officer | Profile |
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Metro Medical Supply is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Patient Interaction is a Bronx, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
U M W A Health and Retirement Fund is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
To improve the health status of the communities we serve through compassionate, high quality, accessible and cost effective care. We value those who provide our care and those who receive our care. We accomplish this through partnership, dedication, service, quality and stewardship.